DC
AARD

Diametric Capital’s Aardvark Therapeutics AARD Stock Holding History

Diametric Capital’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,309
Closed -$253K – 612
2025
Q4 		$253K Buy
+19,309
New +$241K 0.07% 322

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Diametric Capital's AARD Position: Q1 2026 in Review

Diametric Capital sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 19,309 shares — an estimated $253K sold.

Diametric Capital first reported a position in AARD in Q4 2025 and held it in 1 quarter. The position peaked at $253K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Diametric Capital reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Diametric Capital sold 19,309 Aardvark Therapeutics shares in Q1 2026, an estimated $253K.
  • Diametric Capital first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 1 quarter.
  • Diametric Capital's Aardvark Therapeutics position peaked at $253K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.